Harel Insurance Investments & Financial Services Ltd. Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Harel Insurance Investments & Financial Services Ltd. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 97.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60 shares of the biopharmaceutical company’s stock after selling 2,418 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Regeneron Pharmaceuticals were worth $42,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Benjamin Edwards Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $33,000. Delos Wealth Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $33,000. Byrne Asset Management LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $34,000. Addison Advisors LLC grew its stake in Regeneron Pharmaceuticals by 220.0% in the first quarter. Addison Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 33 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in Regeneron Pharmaceuticals by 83.3% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 55 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 83.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ:REGN opened at $587.28 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $538.01 and a 12-month high of $747.42. The company has a market capitalization of $63.74 billion, a PE ratio of 8.32, a PEG ratio of 1.77 and a beta of 0.31. The business has a 50 day moving average of $613.60 and a two-hundred day moving average of $637.99. The company has a current ratio of 4.76, a quick ratio of 4.09 and a debt-to-equity ratio of 0.14.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $11.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.37 by $2.12. Regeneron Pharmaceuticals had a return on equity of 50.10% and a net margin of 48.06%. The company had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the previous year, the company posted $10.09 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 17.2% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 41.3 EPS for the current year.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. Evercore ISI set a $635.00 price target on Regeneron Pharmaceuticals in a research note on Monday, June 20th. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $610.00 to $619.00 and gave the stock an “equal weight” rating in a research note on Friday, July 15th. StockNews.com upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, July 3rd. Cowen boosted their price target on Regeneron Pharmaceuticals from $635.00 to $645.00 in a research note on Wednesday, July 20th. Finally, Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $750.00 to $735.00 and set an “overweight” rating on the stock in a research note on Friday, June 3rd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $697.15.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of the business’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $656.97, for a total value of $722,667.00. Following the completion of the transaction, the executive vice president now directly owns 19,644 shares of the company’s stock, valued at $12,905,518.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $650.78, for a total transaction of $65,078.00. Following the completion of the transaction, the director now directly owns 22,182 shares of the company’s stock, valued at approximately $14,435,601.96. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Marion Mccourt sold 1,100 shares of the company’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $656.97, for a total value of $722,667.00. Following the transaction, the executive vice president now directly owns 19,644 shares of the company’s stock, valued at $12,905,518.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,300 shares of company stock valued at $1,434,281. 8.99% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).



Receive News & Ratings for Regeneron Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *